Columbus, OH: August 28, 2018 — WoundWiseIQ continues its expansion as three new leaders join the company.  Edward Quilty, Heather Connell, and Dr. John Phillips bring their collective talents to the team.

Gary Ross, CEO of WoundWiseIQ, notes that the additions bring additional wound care expertise, “We have always had strong business and technology talent on the team, but now with the addition of Ed, Heather and Dr. Phillips, we are building wound care thought leadership; People who have walked in our customer’s shoes trying to heal wounds more effectively.”

Ed Quilty, who joins the company’s board of directors, has been the CEO of four publicly traded heath care and wound care companies.  This includes Palatin Technologies, Inc. – a biopharmaceutical company specializing in peptide drug design for diagnostic and therapeutic agents-, MedChem Products, Inc. – a developer and manufacturer of specialty medical products which was acquired by C. R. Bard- , and Life Medical Sciences, Inc. – a developer and manufacturer of specialty medical products including wound healing agents which was purchased by MedChem Products, Inc.

Heather Connell, joins the company as WoundWiseIQ Customer Success Manager.  She has been active in the Clinical Research Field of Wound Healing, most recently serving as Clinical Research Manager for the SerenaGroup.  Her decade-long research focuses on wounds related to Diabetes and/or Chronic Venous Insufficiency. Her participation in the research process spans from protocol writing and development, data collection, data and compliance monitoring, final data analysis, and photographic wound area adjudication.  She received certification as a Clinical Research Professional in 2012 from SoCRA.

OhioHealth physician Dr. John Phillips is joining the WoundWiseIQ physician’s advisory board, and is a heart and vascular physician bringing more than 10 years of knowledge of healing and vascular wound care.  Dr. Phillips has invented a wound care software application himself, and is working with the team to develop predictive analytics and telehealth software products and to support those through clinical trials.